Loading stock data…
TRVI
$13.87+0.11 (+0.80%)
Pre-Market$13.93+0.06 (+0.43%)· Last close May 1
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Trevi Therapeutics, Inc. in the Healthcare sector is trading at $13.87. The stock is currently 14% below its 52-week high of $16.12, remaining 29.9% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why TRVI maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.87
Potential Upside
5%
Whystock Fair Value$14.56
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$21.91+58.0%
Range$16.00 – $27.00
Fundamentals
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.55%
Volume
Today's trading volume
1.14M
Recent News
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?
Trevi Therapeutics recently closed an underwritten public offering of 13,340,000 common shares, raising approximately US$173 million before fees, and separately proposed doubling its authorized common stock to 400,000,000 shares via an amendment to its Delaware certificate of incorporation. The combination of a sizeable capital raise and a request for significantly more authorized shares gives Trevi added financial flexibility for future financing, partnering or incentive programs without...
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Take Positions Amid Corporate Earnings
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad
A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough
Trevi Therapeutics (TRVI) recently completed its end of phase 2 meeting with the FDA for its idiopathic pulmonary fibrosis related chronic cough program. This gives investors a clearer view of the regulatory path ahead. See our latest analysis for Trevi Therapeutics. The FDA update appears to have supported sentiment, with a 1 day share price return of 3.11% and 7 day share price return of 5.38%, even though the 30 day share price return of negative 10.23% shows some recent cooling. Over a...
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Trevi Therapeutics Q4 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in two chronic cough programs. President and CEO Jennifer Good said 2025 marked a “major inflection po